July , 2018
Crohn’s Disease is a debilitating form of chronic inflammatory bowel disease (IBD). It is estimated that 3 million people in the US alone have a form of IBD. There is currently no cure for Crohn’s which is usually characterized by frequent diarrhea, abdominal pain, unexplained weight loss, fatigue, and anemia. Normal therapies include immunosuppressive drugs including steroids, but 80% of patients will need surgical intervention within 20 years of diagnosis. There is evidence that low dose naltrexone can achieve symptom relief in some patients who have moderate symptoms despite normal therapies.
When you hear the word naltrexone your first instinct is most likely to think of this medication as something that is used to treat opioid or alcohol dependence. However, what if I were to tell you that patients suffering with fibromyalgia could use this medication to find relief and treat their pain? As strange as this may sound, breakthroughs in research in the recent years have actually shown that low dose naltrexone may potentially have a multitude of uses, including treating autoimmune diseases, pain and central nervous system disorders. This article will explore why low dose naltrexone may be not be such a far-fetched idea for treating fibromyalgia.
Biotin goes by several other names: vitamin H, vitamin B7, and coenzyme R. Biotin is an essential molecule to biological processes which cannot be produced in the body. Like all vitamins, it must be ingested in the diet. Currently, high dose biotin at a dose of 300 mg every day is being clinically investigated for the improvement of symptoms in progressive forms of multiple sclerosis (MS). This dose is 10,000 times higher than the adequate daily intake recommendations.
Ketamine is a drug currently approved by the FDA for use as a general anesthetic during minor surgical procedures such as biopsies. It is widely known as a recreational drug because of its ability to induce cognitive-dissociative, hallucinogenic, and euphoric states in humans. Recently, it has been implicated in research as a potential therapeutic agent in depression especially in patients who have failed previous standard therapies.
Overview: Patients with extensive vitiligo may choose to depigment the remaining areas of their skin to attain uniform skin tone. Monobenzone or monobenzyl ether of hydroquinone (MBEH) is a drug approved by the FDA for final depigmentation of the skin in patients with advanced vitiligo (vitiligo universalis). It is prepared as a 20-40% topical formulation such as a cream or ointment and is applied twice a day to affected areas. Monobenzone has been shown to start irreversibly depigmenting skin in 1-4 months, and full effects are usually seen after 5-12 months. Beside are pictures showing the progression of a patient’s depigmentation before, and at 4, 6, and 8 months of monobenzone treatment.